RCVS, or reversible cerebral vasoconstriction syndrome, is a condition where arteries in the brain suddenly tighten and narrow, causing intense, explosive headaches that peak within seconds. The narrowing typically resolves on its own within three months, but in a minority of cases it can lead to serious complications like stroke or bleeding in the brain.
RCVS most commonly affects people between ages 42 and 47, with women outnumbering men by roughly 2 to 8 times depending on the study. Men with RCVS tend to be about a decade younger than women, typically presenting in their 30s compared to women in their late 40s. In children and adolescents, the pattern flips: up to 85% of cases are male.
What Happens in the Brain
The core problem in RCVS is a loss of control over blood vessel tone in the brain. Normally, your brain’s arteries expand and contract smoothly to regulate blood flow. In RCVS, an excessive burst of sympathetic nervous system activity causes arteries to clamp down in multiple segments at once. The nerve endings along these arteries release signaling chemicals that force the vessel walls to contract, while smaller blood vessels deeper in the brain may actually widen at the same time. This push and pull between constriction and dilation is what makes the syndrome so unpredictable.
The lining of the blood vessels also stops functioning properly. During the acute phase, the vessels lose their ability to adjust to normal changes in blood flow. When this dysregulation becomes severe enough, the protective barrier between the bloodstream and brain tissue can break down, which is when bleeding or swelling complications become possible.
The Thunderclap Headache
The hallmark of RCVS is a “thunderclap headache,” a headache that rockets to maximum intensity within 60 seconds. It’s often described as the worst headache of a person’s life. The pain tends to be bilateral and concentrated at the back of the head, lasting around three hours before fading completely.
These headaches don’t just happen once. They recur in 85% to 90% of patients, typically striking about once a week for up to four weeks. The good news is they generally become less intense and less frequent over that span. Most people’s headaches resolve entirely within two to three weeks, even though the underlying vessel narrowing takes longer to clear. Some patients experience only the headaches, with no other neurological symptoms at all.
Common Triggers
A triggering substance or event can be identified in up to 70% of RCVS cases. The most frequently implicated triggers are medications and drugs that affect blood vessel tone:
- Migraine medications: triptans and ergotamines, which is especially problematic since patients often take these to treat the very headaches RCVS causes
- Antidepressants: SSRIs and SNRIs
- Decongestants: pseudoephedrine and similar over-the-counter cold medications
- Stimulants: cocaine, amphetamines, diet pills, and energy-boosting supplements containing ephedrine
- Newer migraine preventives: CGRP inhibitors, a class of medications used for chronic migraine, have been linked to RCVS onset and worsening in case reports
The postpartum period is another well-recognized trigger. About 7% to 9% of RCVS cases occur within one month of delivery. Postpartum RCVS tends to recur more often without an identifiable drug trigger compared to other forms. Women with a history of migraine appear to face higher risk.
The remaining 30% of cases are considered spontaneous, with no clear precipitant.
How RCVS Is Diagnosed
Diagnosing RCVS can be tricky because the headaches mimic other dangerous conditions, particularly a ruptured brain aneurysm. The first step is usually a CT scan and sometimes a spinal tap to rule out subarachnoid hemorrhage from an aneurysm. In RCVS, the spinal fluid is typically normal unless bleeding has already occurred as a complication.
The definitive finding comes from imaging the blood vessels themselves using CT angiography (CTA) or MR angiography (MRA). The classic appearance is a “string of beads” or “sausage on a string” pattern, where arteries show alternating segments of narrowing and dilation across multiple vessels in both hemispheres. This pattern affects multiple arteries simultaneously and tends to be relatively symmetrical.
One important caveat: about 20% of patients have normal-looking brain imaging at their initial presentation, even though the blood vessel imaging is abnormal. The vasoconstriction itself peaks around 16 days after symptoms begin, so early scans can underestimate the severity. The diagnosis is confirmed when follow-up imaging shows the narrowing has resolved, typically within three months.
RCVS vs. Brain Vasculitis
The condition most commonly confused with RCVS is primary angiitis of the central nervous system (PACNS), a rare inflammatory disease of brain blood vessels. Distinguishing the two matters enormously because their treatments are nearly opposite: PACNS requires aggressive immune suppression, while steroids may actually worsen RCVS.
Several features help tell them apart. Spinal fluid in PACNS typically shows elevated protein and inflammatory cells, while RCVS spinal fluid is normal. On brain imaging, PACNS almost always shows ischemic damage, while RCVS may show brain swelling or surface-level bleeding instead. The vessel wall itself provides a clue too: in PACNS, the artery walls show signs of inflammation and light up on specialized imaging sequences, while RCVS vessel walls do not. Most importantly, RCVS improves over weeks to months, while PACNS is progressive without treatment.
Complications and Risks
While RCVS is called “reversible,” it can cause lasting damage in a significant minority of patients. A systematic review of nearly 2,750 patients found that about 16% experienced an ischemic stroke (caused by blocked blood flow), roughly 22% had some form of bleeding in the brain, and an additional 20% had bleeding along the brain’s surface. Brain swelling occurs in about 10% of cases, usually within the first week, and typically resolves within a month.
These complications tend to follow a pattern. Bleeding and swelling happen earlier in the course, while ischemic strokes tend to occur later as the vasoconstriction peaks. Risk factors for hemorrhagic complications include female sex, a history of migraine, and age over 45.
Treatment and Recovery
There are no formal treatment guidelines for RCVS, and no large clinical trials have established a standard approach. The most widely used medication is nimodipine, a calcium channel blocker that relaxes blood vessel walls. It’s typically started as soon as RCVS is suspected and continued for about three months, with the dose adjusted based on how well the headaches respond. In studies, most patients do well on a moderate dose, though a small percentage (around 8 to 9%) need higher doses for persistent or recurring headaches.
Equally important is removing any triggering substance. If you were taking an SSRI, a decongestant, or a triptan, those medications are stopped immediately. Patients are generally advised to avoid all vasoactive substances during recovery and potentially long term. Physical exertion, straining, and sexual activity, all of which can provoke thunderclap headaches during the acute phase, are typically limited until symptoms resolve.
The overall prognosis is favorable for most people. Headaches resolve within weeks. The arterial narrowing clears within three months. Most patients recover fully without lasting neurological deficits. Recurrence of RCVS after the initial episode is possible, particularly in patients over 45, but it is not the norm.